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To analyze HTLV-1 cytotropism, we developed a highly sensitive vaccinia virus-based assay measuring activation of a reporter gene upon
fusion of two distinct cell populations. We used this system in a functional cDNA screening to isolate and confirm that the glucose transporter
protein 1 (GLUT-1) is a receptor for HTLV-1. GLUT-1 is a ubiquitously expressed plasma membrane glycoprotein with 12 transmembrane
domains and 6 extracellular loops (ECL). We demonstrate for the first time that peptide antibodies (GLUT-IgY) raised in chicken to the large
extracellular loop (ECL1) detect GLUT-1 at the cell surface and inhibit envelope (Env)-mediated fusion and infection. Efficient GLUT-IgY
staining was detected with peripheral blood CD4+ lymphocytes purified by positive selection. Further, GLUT-IgY caused efficient inhibition of
Env-mediated fusion and infection of CD4+ T and significantly lower inhibition of CD8+ T lymphocytes. The specificity of GLUT-IgY antibodies
to GLUT-1 was demonstrated by ECL1 peptide competition studies. Grafting ECL1 of GLUT-1 onto the receptor-negative GLUT-3 conferred
significant receptor activity. In contrast, grafting ECL1 of GLUT-3 onto GLUT-1 resulted in a significant loss of the receptor activity. The ECL1-
mediated receptor activity was efficiently blocked with four different human monoclonal antibody (HMab) to HTLV-1 Env. The ECL1-derived
peptide blocked HTLV-1 Env-mediated fusion with several nonhuman mammalian cell lines. The results demonstrate the utilization of cell surface
GLUT-1 in HTLV-1 infection of CD4+ T lymphocytes and implicate a critical role for the ECL1 region in viral tropism.
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The human T cell leukemia virus type 1 (HTLV-1) was the
first human retrovirus to be characterized (reviewed in Gallo,
2005; Yoshida, 2005). HTLV-1 causes a broad spectrum of
diseases, including adult T cell leukemia–lymphoma and is the
only human retrovirus known to be an etiological agent of
cancer. The virus is transmitted by sexual contact, via bloodAbbreviations: PBMCs, peripheral blood mononuclear cells; Env,
envelope glycoprotein; Env63, wild-type HTLV-1 envelope glycoprotein;
Unc63, a cleavage mutant of HTLV-1 Env63 defective in syncytium
formation; wt, wild type.
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feeding (reviewed in Feuer et al., 1996). HTLV-1 has been
found primarily in lymphocytes of infected patients and is
primarily tropic for CD4+ T lymphocytes (reviewed in Feuer
et al., 1996; Overbaugh, 2004). This restricted cell tropism in
vivo is in sharp contrast with the remarkably extended tropism
observed for both HTLV types in vitro.
The envelope glycoprotein (Env) of the HTLV-1 virus
mediates receptor binding and membrane fusion, two separate
but related functions. The Env protein of HTLV-1 virions
includes an external surface glycoprotein, gp46, and a non-
covalently associated transmembrane anchor protein, gp21. In
HTLV-1-infected cells, Env is initially translated as a large
common gp63 precursor that is subsequently cleaved to produce
the external receptor-binding gp46 subunit and the membrane-
bound gp21 subunit. Proteolytic cleavage of gp63 is thought to
expose the hydrophobic N-terminus of gp21 that can potentially
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fusion (reviewed in Feuer and Green, 2005; Manel et al., 2005a,
2005b).
Recent biochemical studies identified the glucose trans-
porter protein GLUT-1 as a receptor for HTLV-1 and HTLV-2
(Manel et al., 2003a). The mammalian GLUT genes belong to
a large superfamily of genes whose protein products are
involved in the transport of a variety of hexoses and other
carbon compounds. The most characteristic feature of these
proteins is the presence of 12 hydrophobic transmembrane
(TM) domains, 6 extracellular loops (ECL), and 7 intracellular
domains (Mueckler, 1994). Human GLUT-1 exhibits about
97–98% sequence identity with the analogous rat, mouse,
rabbit, and pig proteins. Human GLUT-1 and GLUT-3 share
65% amino acid homology, but their C-terminal domains
and ECL domains are distinctive (Mueckler, 1994). Greater
than 50% of the homology between mammalian GLUT-1
proteins is localized within the TM domains while most of the
divergent amino acids occur in the ECL and intracellular
loops.
The exact role of GLUT-1 in HTLV-1 Env-mediated fusion
and viral infection are not completely understood. Further-
more, it remains unknown whether the virus utilizes this
receptor to infect CD4+ T lymphocytes. Recent studies
demonstrated that expression of GLUT-1 in MDBK cells
increased susceptibility to HTLV-1-mediated syncytia forma-
tion and viral infection (Coskun and Sutton, 2005). However,
direct evidence for the involvement of GLUT-1 in HTLV-1
Env-mediated cell fusion is still lacking. To determine the
role of GLUT-1 in Env-mediated fusion and viral infection,
we generated novel peptide antibodies to the large ECL1
domain of GLUT-1. ECL1 antibodies block Env-mediated
fusion and infection of mammalian cell lines providing a
molecular evidence to explain the ability of HTLV-1 to infect
a wide range of cell lines in vitro. We show for the first time
that HTLV-1 Env-mediated fusion and infection of primary
CD4+ T lymphocytes are sensitive to ECL1 antibodies.
Analysis of GLUT-1/GLUT-3 hybrid receptors demonstrated
that the ECL1 domain mediates a significant level of the
GLUT-1 receptor activity. We demonstrate that ECL1 domain
alone is sufficient to confer receptor activity. Human
monoclonal antibodies (HMab) to HTLV-1 Env showed
selective inhibition through ECL1 domain. The results
implicate a critical role for ECL1 domain in Env interaction
and cytotropism.
Results
GLUT-1 confers susceptibility to Env-mediated fusion and
pseudotyped virus infection
In our culture system, NIH 3T3 cells express the lowest
levels of endogenous GLUT-1 and show low signals in our
HTLV-1 Env-mediated fusion assays. To determine if GLUT-1
could render the poorly permissive NIH 3T3 cells highly
permissive to HTLV-1 Env-mediated fusion, we transfected the
murine cells with plasmid DNA encoding either GLUT-1 orGLUT-3. HTLV-1 does not bind GLUT-3 (Manel et al., 2003a),
a glucose transporter protein with high amino acid homology to
GLUT-1 (Mueckler, 1994). Fig. 1A shows that transfection of
GLUT-1 cDNA into NIH 3T3 cells conferred higher suscep-
tibility to Env-mediated fusion. This fusion signal was not
observed with NIH 3T3 cells transfected with GLUT-3. Similar
results were obtained when viral particles pseudotyped with
Env63 were used to infect either GLUT-1 or GLUT-3-
transfected murine NIH 3T3 cells. GLUT-1, but not GLUT-3-
transfected, murine cells allowed virus infection as measured by
luciferase production (Fig. 1B). The negative control in the
infection assays was a pseudotyped virus that carried the
cleavage-defective Unc63. VSV fusion was used as a positive
control to show the competence of transfected cells for viral
infection (Fig. 1C). Expression of GLUT proteins in transfected
cells was verified by Western blot analysis using specific
antibodies to either GLUT-1 (Fig. 1D) or GLUT-3 (Fig. 1E) as
described in Methods and methods section.
Characterization of GLUT-IgY antibodies
To examine cell surface expression of GLUT-1 and in-
vestigate the role of ECL1 domain, we generated GLUT-IgY
polyclonal antibodies against the ECL1 region of GLUT-1
in chicken. IgY is the immunoglobulin produced in chicken and
is the equivalent of IgG in mammalian species. Chicken egg
yolk IgY from immunized hens has considerable advantages for
the production of polyclonal antibodies because of the
phylogenetic distance between birds and mammals as wells as
noninvasive collection. Our choice was based on the fact that
the chicken GLUT-1 is the least homologous to the human
counterpart. Sera from immunized animals have been shown to
bind specifically to the ECL1 peptide in concentrations >1/104
(data not shown).
To examine the specificity of GLUT-IgY for ECL1, we
tested whether ECL1 peptide competes for binding to GLUT-
1. HeLa cells were mixed with different amounts of a control
peptide or ECL1 peptide and then stained with GLUT-IgY.
Fig. 2A shows the results of the FACS staining as a result of
mixing HeLa cells with either peptide at a concentration of
100 μg/ml. The results show that ECL1 peptide efficiently
competes for binding since FACS staining was significantly
reduced in the presence of ECL1 peptide. In contrast, the
control peptide had no significant effect on GLUT-IgY stain-
ing of HeLa cells.
To determine whether GLUT-IgY specifically binds to
GLUT-1 and not other molecules in the GLUT family, we
used CHO cells expressing recombinant GLUT-1 or GLUT-3, a
homologous glucose transporter. Efficient blocking of GLUT-
IgY staining occurred in the presence of ECL1 peptide but not
the control peptide (Table 1). To confirm the specificity of
ECL1 peptide binding, we examined its effect on the reactivity
of anti-GLUT-3 antibodies. The ECL1 peptide had no
significant effect on FACS staining of GLUT-3 expressed in
transfected cells (Table 1). The drop observed with ECL1
peptide and not with the control peptide confirms the utilization
of endogenous mammalian GLUT-1.
Fig. 1. Human GLUT-1 supports HTLV-1 Env-mediated fusion and infection. (A) Target NIH 3T3 cells were transfected with the plasmid DNA indicated on the x-axis
and used in Env-mediated fusion assay. The fusion-defective Unc63 control, wt Env63, or VSV G was individually expressed in 293 cells coexpressing PT7-lacZ. The
effector 293 cells were mixed with transfected NIH 3T3 target cells expressing vector, GLUT-1, or GLUT-3 proteins. After incubation for 3 h, the amount of β-
galactosidase activity was measured. (B and C) NIH 3T3 cells transfected with the plasmids (labeled at the x-axis) were infected with the indicated pseudotyped viral
particles at an moi of 1 ng/ml. Infectivity was evaluated 72 h postinfection by measuring luciferase production. Expression of GLUT-1 (D) and GLUT-3 (E) in
transfected NIH 3T3 cells was verified by Western blot analysis using specific antibodies to either protein as described in Materials and methods. Lanes 3, 1, and V
correspond to GLUT-3-, GLUT-1-, or vector-transfected NIH 3T3 cells. The numbers on the left correspond to the positions of molecular weight marker. These results
are representative of at least three different experiments. Kd, kilodalton; OD, optical density.
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lymphocytes and mammalian cell lines
We performed indirect staining on a number of mammalian
cell lines using the GLUT-IgY as the primary antibodies.
Freshly isolated/uncultured human CD4+ T cells were used as
a negative control since they do not express surface GLUT-1.
The FACS analysis demonstrated that the GLUT-IgY antigen
was present at high levels on some human cell lines but
poorly detected on a number of nonhuman cell lines. Fig. 2BFig. 2. GLUT-IgYantibodies detect cell surface GLUT-1. (A) ECL1 peptide efficientl
control peptide (HKDLCPQIWSGCESL) or ECL1 peptide (WVHRYGESILPTTLT
serum or GLUT-IgYand analyzed by FACS. The shaded area represents staining with
upper left corner represent the mean fluorescence intensity. The cells were enginee
containing PT7-lacZ. Following a 3 h incubation, Env-mediated fusion was assessed
the HTLV-1 Env-mediated fusion index. The fusion index is the ratio of the β-gal un
fusion values obtained with VSVare: 75 (Fresh CD4+T), 130 (HeLa), 145 (HeLa.T4),
87 (3T3.T4), 79 (BSC-1), 89 (CHO). These results were reproducible in 4 indepen
affinity-purified CD4+ and CD8+ T lymphocytes cultured in the absence (unstimulated
with either preimmune (C) or GLUT-IgY serum (D) and either PE-conjugated anti
detected by using an FITC-labeled secondary antibody as described in Materials and
that are positive in the respective quadrant are indicated. The figure shows primary d
nine others.shows the corresponding histograms with the mean fluores-
cence intensity indicated at the upper left corner. Poor
staining was also observed with the human Jurkat and 293
cells. We tested a variety of mammalian cell lines as targets in
an Env-mediated fusion assay. A number of mammalian cell
lines produced positive signals above the Unc63 control in
the cell fusion assay. In terms of signal to background ratio,
the extent of cell fusion varied across different cell lines. Cell
lines of human origin produced the highest signals. The
highest signal to background ratio was observed with HeLa.y competes for binding of GLUT-IgY. HeLa cells were mixed with 100 μg/ml of
C) then stained with GLUT-IgY. (B) Cells were stained with either preimmune
the GLUT-IgYantibodies overlaid over preimmune staining. The numbers at the
red to express T7 RNA polymerase and mixed with Env-expressing 293 cells
by measuring β-galactosidase. The numbers at the bottom right corner represent
its produced with Env63 divided by those obtained with the control Unc63. The
140 (TK−), 151 (Jurkat), 135(293cells), 125 (BHK), 85 (NIH 3T3), 91 (MDBK),
dent experiments. (C and D) Flow cytometric analysis of freshly isolated and
) or presence (stimulated) of PHA/IL-2 for 3 days. The cells were double stained
-CD4 or anti-CD8 monoclonal antibodies. The surface GLUT-1 was indirectly
methods. The cell treatment is indicated to the top of plots. Percentages of cells
ata from one individual and Table 2 summarizes the results from this donor and
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mediated fusion by the Unc63 background, is indicated at the
right bottom corner of each histogram (Fig. 2B). Interestingly,
poor staining of GLUT-1 correlated with the low Env-mediated fusion signal except for 3T3.T4 cell line (Fig. 2B).
VSV Env-mediated fusion was used as a positive control to
show competence of all cell lines to undergo cell fusion (cited
in the legend to Fig. 2).
Table 1
Specificity of GLUT-IgY to GLUT-1a
DNA transfected Vector DNA pGLUT-1 pGLUT-3 pGLUT-3
Antibody GLUT-IgY GLUT-IgY GLUT-IgY Anti-GLUT-3
Peptide Mean fluorescence intensity
None 10.5 55 11.3 35
Control peptide 10.8 49.5 11.8 31.6
ECL1 peptide 2.5 11 2.6 32.4
a CHOcellswere transfectedwithplasmidDNAencodingGLUT-1(pGLUT-1),
GLUT-3 (pGLUT-3), or empty vector under vaccinia early/late promoter.
Expression of the proteins was activated by infection with vaccinia recombinant
vTF7-3. The infected cells were incubated alone or with control or ECL1 peptide
(100 μg/ml) then stained with either GLUT-IgY or anti-GLUT-3 antibodies.
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to CD4+ T lymphocytes in vivo, we examined cell surface
staining of GLUT-1 in the different lymphocyte populations.
Total PBMCs were used to isolate CD4+, CD8+, CD14+, and
CD19+ cell populations. These primary cell populations were
cultured with or without PHA + IL-2 in 10% FBS for 3 days
before FACS analysis. Staining of CD4+ and CD8+ T
lymphocytes with preimmune serum represented the back-
ground signal (Fig. 2C). FACS analysis performed immediately
after isolation of CD4+ or CD8+ showed no significant staining
with GLUT-IgY (shown in Fig. 2B). However, after 3 days in
culture, the percentage of double positive cells coexpressing
CD4 and GLUT-1 was 4 to 7 times higher than those
coexpressing CD8+ and GLUT-1 (Fig. 2D and Table 2).
PHA + IL-2 stimulation of CD4+ and CD8+ cells resulted in
upregulation of GLUT-1 expression. These results suggest that
the majority of CD4+ T lymphocytes express GLUT-1 without
PHA/IL-2 activation. Cell activation increased the intensity of
GLUT-1 in both CD4+ and CD8+ T cell populations.
Immunoblot analysis of GLUT-1 expression
Quantitative immunoblots (probed with commercial anti-
bodies generated against the GLUT-1 cytoplasmic C-terminus)Table 2
Ratio of the mean fluorescence index of GLUT-IgY staining in human
lymphocytes and efficiency of blocking Env-mediated fusion a
Donor CD4+ CD8+ CD14+ CD19+ % blocking
CD4+ b
% blocking
CD8+ b
1 120 26 9.0 8.1 92 30
2 170 31 7.6 6.8 85 18
3 110 22 7.3 6.5 60 25
4 126 24 6.0 ND 70 18
5 130 20 6.4 7.3 50 17
6 140 23 5.1 ND 52 30
7 104 27 6.0 6.8 55 26
8 97 21 ND ND 80 19
9 134 17 7.6 8.6 90 15
10 93 18 7.2 8.4 48 29
a Primary cell populations were cultured in RPMI containing 10% FBS
without PHA or IL-2. The mean fluorescence indexes were calculated by
dividing the mean intensity obtained with GLUT-IgY by the mean intensity of
background staining obtained with pre-immune serum.
b Percent blocking of Env-mediated fusion.of GLUT-1 present in membrane fractions of several mamma-
lian cell lines revealed that GLUT-1 was expressed as two bands
above the 50 kDa marker protein (Fig. 3A). This is consistent
with previous work reporting the detection of GLUT-1 as a
broad band between 45 and 65 kDa (Mueckler, 1994).
Densitometer scanning indicated that HeLa, HeLa.T4, TK−,
and 3T3.T4 cell lines expressed higher levels of membrane
GLUT-1 (Fig. 3A). With the exception of 3T3.T4, the
nonhuman cell lines tested had significantly lower endogenous
levels of GLUT-1 (Fig. 3A). Human HeLa.T4, HeLa, and TK−
cell lines expressed a slower migrating GLUT-1 (Fig. 3A) and
showed the highest fusion values that correlated with cell
surface staining of GLUT-1 (Fig. 2B). The results demonstrate
that in most human cell lines the higher intensity of GLUT-1
seems to correlate with the efficiency of HTLV-1 Env-mediated
fusion.
Analysis of membrane-associated GLUT-1 by immunoblot-
ting demonstrated the expression of multiple forms of GLUT-1
in both CD4+ and CD8+ T lymphocytes (Fig. 3B). Consistent
with previous data in the literature, freshly isolated CD4+ Tcells
lack GLUT-1 expression. However, GLUT-1 expression was
restored in CD4+ T lymphocytes cultured in 10% serum (Fig.
3B). Expression of different sizes of the protein may suggest
different protein processing in the different cell populations.Fig. 3. Immunoblot analysis of GLUT-1 expression. Quantitative Western blot
analysis of membrane-bound GLUT-1 protein isolated from several mammalian
cell lines. Equivalent amounts of protein samples prepared from the indicated
mammalian cell lines (A) or peripheral blood T lymphocytes (B) were analyzed
in 10% SDS-PAGE and transferred into PVDF membranes by blotting. After
blocking, the blots were probed with antibodies to the last 12 amino acids of
human GLUT-1 C-terminus that is identical in all cell lines tested. The blots
were stripped and reprobed with antibodies against GAPDH to control for gel
loading. Arrows indicate the position of GLUT-1 protein bands.
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To examine the effect of the GLUT-IgY antibodies on Env-
mediated fusion, we preincubated the antibodies with the HeLa.
T4 target cells before mixing them with Env-expressing cells.
GLUT-IgY antibodies resulted in ∼70% inhibition of Env-
mediated fusion (Fig. 4A) and pseudotyped virus infection of
HeLa.T4 cells (Fig. 4B) but had no effect on VSV infection
(Fig. 4C). Complete inhibition of HTLV-1 infection was
consistently observed with PRH-11A (Fig. 4D). Preincubation
with preimmune serum had no effect on HTLV-1 Env-mediated
fusion (Fig. 4A) or viral infection (Fig. 4B). These results
demonstrate the utilization of GLUT-1 as a receptor on HeLa.T4
cells and suggest that the ECL1 region is critical for Env-
mediated fusion and viral infection.
GLUT-1 is a receptor utilized by HTLV-1 to infect CD4+
T lymphocytes
To determine the role of GLUT-1 in HTLV-1 Env-mediated
fusion and infection of primary T lymphocytes, we first
examined the ability of affinity-purified target cell populations
to undergo cell fusion with HTLV-1 Env-expressing cells. TheFig. 4. GLUT-IgYantibodies specifically block HTLV-1 Env-mediated fusion and infe
increasing concentrations of the indicated antibodies. Following the preincubation pe
were added and the mixture incubated for 2 h at 37 °C. Measuring β-gal produced ass
Increasing concentrations of the indicated antibodies were added to HeLa.T4 cells, inc
VSV (C). The luciferase activity, indicative of viral infectivity, was measured 48 h p
directed against HTLV-1 gp46 that has been shown to block syncytia formation (Had
(CMV).results indicated efficient Env-mediated fusion with CD4+ T
lymphocytes and low Env-mediated fusion with CD8+ T cells
(Table 2). The competence of the purified cell populations to
undergo cell fusion was confirmed with VSV Env-expressing
cells (data not shown). We analyzed the effect of preincubating
GLUT-IgY antibodies with affinity-purified CD4+ T cells. A
dose-dependent inhibition of HTLV-1 Env-mediated fusion was
observed when the CD4+ T cells isolated from some donors
were preincubated with increasing concentrations of GLUT-IgY
but not with preimmune serum (data not shown). The inhibitory
effect of GLUT-IgY varied from 50–92% across 10 donors
examined (Table 2).
To examine whether blocking the first step of viral entry
leads to blocking virus infection we performed the blocking
experiments using virus particles pseudotyped with HTLV-1
Env. Unstimulated CD4+ T cells were slightly susceptible (Fig.
5A) but unstimulated CD8+ T, CD14+, and CD19+ cells were
relatively resistant to infection (data not shown). In the
absence GLUT-IgY, PHA/IL-2-stimulated CD4+ T lympho-
cytes showed the highest luciferase signals in the infection
assays whereas stimulated CD8+ T cells produced significantly
lower luciferase signals (Fig. 5A). The competence of cell
populations for infection was verified using VSV pseudotypedction. (A) HeLa.T4 cells expressing PT7-lacZwere preincubated for 30 min with
riod effector 293 cells expressing HTLV-1 Env63 and T7 RNA polymerase cells
essed the effect of GLUT-IgYantibodies on Env-mediated fusion. (B, C, and D)
ubated for 30 min at 37 °C then infected with pseudotyped HTLV-1 (B and D) or
ostinfection and is expressed as relative light units (RLU). PRH-11A is a mAb
lock et al., 1997). Control antibody is a mAb directed against cytomegalovirus
Fig. 5. GLUT-IgY blocks HTLV-1 infection of CD4+ T lymphocytes. Affinity-purified cell populations indicated at the bottom of each graph were cultured in RPMI
containing 10% FBS for 3 days in the absence (unstimulated) or presence (stimulated) of PHA/IL-2. The cell populations were infected with viral particles (moi of
1 ng/ml) pseudotyped with either Unc63 or Env63 (A) or viral particles pseudotyped with VSV G (B). In panels C and D, the purified lymphocytes were pretreated
with increasing concentrations of preimmune or GLUT-IgYantibodies and infected with virus particles containing Unc63 or Env63. Panels C and D represent donors
#1 and #5, respectively. Uns., unstimulated.
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dependent potent inhibition of HTLV-1 infection with CD4+
cells in donor #1 (Fig. 5C) but only partial inhibition of
infection observed with CD4+ T lymphocytes isolated from
donor #5 (Fig. 5D). Treatment with similar concentrations of
preimmune serum had no significant effects on HTLV-1
infection (Figs. 5C and D). The maximum inhibition observed
with CD8+ T lymphocytes was always less than 30% (Figs. 5C
and D). These results provide the first evidence that HTLV-1
infection of CD4+ T lymphocytes is mediated by cell surface
GLUT-1.
ECL1-derived peptide and GLUT-IgY antibodies inhibit
HTLV-1 Env-mediated fusion with mammalian cell lines
To determine whether GLUT-1 expression in mammalian
cell lines can account for the observed wide host range of
HTLV-1, we analyzed the effect of the ECL1-derived peptide
and the antibodies raised against it in an Env-mediated fusion
assay. The ECL1 peptide caused a dose-dependent inhibition of
Env-mediated fusion with HeLa.T4 cells (Fig. 6A). Further-
more, the ECL1 peptide caused efficient blocking of Env-
mediated fusion with a number of mammalian cell lines (Fig.
6B). The control peptide did not cause a significant inhibitory
effect (Figs. 6A and B). To confirm this observation, we usedthe same cell lines preincubated with GLUT-IgY antibodies
before mixing with Env-expressing cells. Preincubation with
GLUT-IgY caused an efficient blocking effect similar to that
seen with the ECL1 peptide (Fig. 6C). The results suggest that
the observed low level of HTLV-1 fusion with nonhuman cell
lines might be attributed to the utilization of mammalian GLUT-
1 as a receptor.
ECL1 domain of GLUT-1 is sufficient to confer efficient
receptor activity
GLUT-1 ECL1 domain is the largest extracellular region
that is predicted to encode 31 amino acid residues. Since
antibodies to this region of GLUT-1 inhibit Env-mediated
fusion, we examined whether grafting this region onto a
receptor-negative molecule (i.e. GLUT-3) confers susceptibil-
ity to Env-mediated fusion. We made two hybrid constructs
using GLUT-1 and GLUT-3 that had their ECL-1 regions
exchanged. The chimeric molecules were referred to as
311111 and 133333; the first number refers to the source of
ECL1 region (Fig. 7A). FACS analysis of transfected murine
cells expressing the different receptor constructs confirmed
that the recombinant proteins were efficiently expressed at the
cell surface (data not shown). This is consistent with recent
finding by Manel et al. (2005a) who reported correct
Fig. 6. ECL1-derived peptide and anti-ECL1 antibodies GLUT-IgY block Env-mediated fusion with mammalian cell lines. (A) Target HeLa cells expressing PT7-lacZ
were preincubated for 30 min with the indicated concentrations of control or ECL1 peptide then mixed with Env-expressing cells and incubated for 2 h. The effect of
the peptides on Env-mediated fusion was assessed by measuringβ-gal produced. (B) The indicated cell lines expressing vaccinia-encoded PT7-lacZwere preincubated
with control or ECL1 peptide for 30 min then mixed with Env-expressing cells expressing T7 RNA polymerase and incubated for 2 h. The effect of peptide was
evaluated by measuring β-gal produced as a result of cell fusion. The dotted line represents the average value of Unc63 background. (C) The same cells in panel B were
preincubated with either preimmune or GLUT-IgY for 30 min and mixed with Env-expressing 293 cells and incubated for 2 h. The effect of GLUT-IgY was assessed
by measuring β-gal produced.
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chimeras including the two we are examining in this study.
Expression of 133333 chimera in murine NIH 3T3 cells
resulted in gain of receptor function as demonstrated in Env-
mediated fusion assays (Fig. 7B). In four different experi-
ments, we estimated an average of 65% gain of receptor
activity. In contrast, expression of 311111 chimera resulted in
the loss of 65% of GLUT-1 receptor activity (Fig. 7B). The
competence of transfected cells to undergo cell fusion was
verified by mixing the cells with VSV Env-expressing cells
(Fig. 7B, lower panel). The different receptor activities of the
constructs were not due to different levels of the protein
expressed in transfected murine cells since anti-His antibodies
detected comparable levels in purified membrane fractions
(Fig. 7C).
To further examine the importance of ECL1 region, we
used a panel of HMab to examine their effect on Env-
mediated fusion by the different receptor molecules. The
results demonstrated that PRH-11A was the most potent
inhibitor and caused >90% inhibition of Env-mediated fusion
conferred by 111111 and 133333 (Fig. 7D). PRH-11A
recognizes an unknown conformational epitope on gp46
(Hadlock et al., 1999). The other HMab (PRH-4, PRH-7A,
and PRH-7B) showed lower inhibitory activity ranged
between 25 and 30%. Interestingly, the potency of inhibition
was similar in cells expressing either wild-type or 133333
receptor. The results suggest that ECL1 region may play a
major role in Env/receptor interaction.
A much lower inhibitory activity was observed with
311111-hybrid receptor. The maximum inhibition of Env-
mediated fusion with cells expressing 311111 was ∼30% (Fig.
7D). We consistently observed an upregulation of Env-
mediated fusion in the presence of PRH-3. These results
suggest that ECL1 is the major but not the only determinant in
Env-mediated fusion. The low receptor activity of 311111suggests that other ECL domains may contribute to HTLV-1
Env-mediated fusion.
Discussion
HTLV-1 infection is initiated by Env binding to a host cell
receptor, fusion of the viral membrane with the host cell
membrane, followed by the release of the viral core into the
cytoplasm of infected cells (reviewed in Manel et al., 2005a,
2005b). Since the discovery of GLUT-1 as a receptor for HTLV-
1/2 (Manel et al., 2003a), research was focused on the role
GLUT-1 plays in HTLV infection. The present study provides
several lines of experimental evidence to show that GLUT-1, in
the plasma membrane, plays a critical role in HTLV-1 Env-
mediated fusion and viral entry. The first piece of evidence was
demonstrated by the functional screening strategy used to
isolate GLUT-1 cDNA (data not shown). The cDNA isolation
was dependent on Env-mediated fusion with murine cells
transfected with HeLa.T4 cDNA clones. Secondly, transfection
of GLUT-1 cDNA into murine cells produces a high signal
when mixed with Env-expressing cells rendering them more
susceptible to Env-mediated fusion. Thirdly, Env-mediated
fusion and infection are sensitive to antibodies that efficiently
react with cell surface GLUT-1. Finally, inhibition of HTLV-1
infection of CD4+ T lymphocytes by GLUT-IgY indicates that
infection is specifically mediated by cell surface GLUT-1.
Consistent with previous data in the literature (Sutton and
Littman, 1996; Trejo and Ratner, 2000), we observed a wide in
vitro host range for HTLV-1. Previous studies demonstrated that
NIH 3T3 cells are permissive for HTLV-1 infection (Jassal et al.,
2001; Manel et al., 2005a, 2005b; Sutton and Littman, 1996;
Trejo and Ratner, 2000). In our hands, NIH 3T3 cells
consistently express the lowest levels of GLUT-1 and show
the lowest Env-mediated fusion signal. This is probably due to
the different culture and serum conditions we use. Serum
Fig. 7. Gain of receptor function by a GLUT-3 chimera containing exchanged GLUT-1 ECL1 domain. (A) A schematic diagram showing the structure of chimeric
receptor constructs. (B) NIH 3T3 cells were transfected with plasmid DNA indicated on the x-axis and expression of receptor molecules was activated by infection
with vTF7-3 (T7 RNA polymerase). The transfecetd cells were mixed with 293 cells expressing HTLV-1 Env63 and PT7-lacZ. The mixtures were incubated for 3 h
and analyzed for the amount of β-galactosidase produced as a result of Env-mediated fusion. A portion of the transfected cells was mixed with cells expressing VSV
Env as a control to show their competence in cell fusion (lower panel). (C) Quantitative Western blot analysis of membrane-bound GLUT-1 protein isolated from
transfected NIH 3T3 cells used in panel B. The blot was probed with antibodies to the His tag inserted at the C-termini of the receptors. The blot was stripped and
reprobed with antibodies against GAPDH to control for gel loading. (D) The Env-expressing cells in panel B were preincubated with the indicated human
monoclonal antibodies for 30 min before mixing with the transfected NIH 3T3 cells. The effect of the monoclonals on Env-mediated fusion was assessed by
measuring β-galactosidase produced.
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expression (Al-Khalili et al., 2003). We observed higher
efficiency of HTLV-1 Env-mediated fusion and viral infection
with most human cell lines. In some cases, this efficiency was
correlated with higher expression levels of membrane-associ-
ated GLUT-1. Different levels of HTLV-1 binding and infection
of mammalian cell lines have previously been observed (Jassal
et al., 2001; Jones et al., 2002; Manel et al., 2003b; Nath et al.,
2003; Trejo and Ratner, 2000). The ability of GLUT-IgY
antibodies to detect cell surface proteins may be affected by the
degree of GLUT-1 glycosylation and ternary interactions with
other proteins. Therefore, the lower detection of cell surface
GLUT-1 in nonhuman cell lines may not reflect the abundance
of this receptor. The lower signal observed with rodent and
primate cell lines might be explained by lower affinity of
HTLV-1 Env to ECL1 domains of nonhuman GLUT-1. The
ECL1 domain contains one N-linked glycosylation site and
most of the divergent amino acids between human andnonhuman species (reviewed in Mueckler, 1994). The observed
different sizes of GLUT-1 in different cell lines may indicate
differences in glycosylation and protein processing which might
contribute to the efficiency of GLUT-IgY staining. Furthermore,
the observed incomplete inhibition of Env-mediated fusion and
viral infection of HeLa.T4 cells may suggest the utilization of an
unknown human-specific coreceptor. The observed higher level
of Env-mediated fusion detected with 3T3.T4 cells may suggest
the utilization of CD4 as a receptor/coreceptor; however, this
possibility needs to be carefully examined. The idea of a HTLV-
1 cofactor or coreceptor has been recently proposed (reviewed
in Manel et al., 2005a, 2005b).
Previous studies analyzing GLUT-1 expression utilized the
receptor-binding domain (RBD) of HTLV envelopes to show
increased HTLV binding protein expression in human T cells
during immune activation (Nath et al., 2003). A significant part
of the observed RBD binding has been attributed to interaction
with cell surface heparin sulfate proteoglycans (HSPG) (Okuma
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antibody probe that specifically detects cell surface GLUT-1
receptor expression. This reagent was critical to measure surface
density of GLUT-1 on primary CD4+ T cells. Recently, Jones
et al. (2005b) demonstrated that HSPGmediates entry of HTLV-
1 into CD4+ T lymphocytes. The study depended on enzymatic
removal of the HS chains of cell surface HSPGs by HS lyase
(Jones et al., 2005b). GLUT-1 has previously been shown to be
N- and O-glycosylated (Ahmed and Berridge, 1999; Samih
et al., 2003). It is possible that the HS lyase treatment affected
cell surface GLUT-1 and resulted in significant reduction in
binding and infection.
We demonstrated that PHA/IL-2 stimulation of CD4+ T
lymphocytes upregulated GLUT-1 levels that correlated with
higher rates of HTLV-1 infection. This is concordant with
recent studies demonstrating that PHA/IL-2 stimulation
increased intracellular GLUT-1 expression that correlated
with enhanced HTLV-1 SU binding and increased titer of
HTLV-1/II pseudotyped viruses (Jones et al., 2005a). It was
previously reported that GLUT-1 was not expressed at
detectable levels in freshly isolated CD4+ T lymphocytes
(Manel et al., 2003b; Nath et al., 2003). This discrepancy
might be due to fact that the studies by Manel et al. and Nath
et al. used CD4+ T cells that were negatively selected whereas
positive selection has been used in the present study. Another
reason is that probably our cells are cultured in 10% FBS for 3
days after isolation. The observed lower infectivity of CD8+ T
lymphocytes may be explained by different posttranslational
modifications, different cell surface context in which GLUT-1
molecules are present, and/or different availability of cor-
eceptors. Similarly, unfavorable levels of GLUT-1 and/or
different protein processing may explain the observed
nonpermissiveness of CD14+ and CD19+ cells.
Several lines of experimental evidence were provided to
suggest a critical role for ECL1 domain in Env-mediated fusion
and viral infection. First, GLUT-IgY antibodies raised against
ECL1 inhibit HTLV-1 Env-mediated fusion and viral infection.
Second, we found that ECL1 region is sufficient to confer
significant receptor activity. Third, the blocking activity of
GLUT-IgY was similar with cells expressing either 133333 or
wild-type GLUT-1 suggesting that ECL1 is a major target for
Env interaction. Finally, blocking HTLV-1 Env-mediated fusion
by the ECL1 peptide provides further evidence for the critical
role of this region in viral entry and tropism. The receptor
activity detected in our 311111 chimera indicates that other
regions of GLUT-1 may also contribute to the receptor activity.
This is consistent with recent data showing that ECL5 and
ECL6 play a role in the Env binding and fusion events (Manel
et al., 2005a). It was recently demonstrated that ECL6 is
required for Env binding while ECL1 is critical for postbinding
events (Manel et al., 2005a). We found that GLUT-IgY
efficiently block human RBC rosetting to cells expressing
HTLV-1 Env, suggesting a role for ECL1 in Env binding (data
not shown). This discrepancy might be due to the different
procedures used to analyze GLUT-1 receptor activity. Further
analysis of different hybrid receptor constructs may be
necessary to confirm these initial studies.We found that PRH-3 Mab upregulated Env-mediated fusion
by >30%. The conformational epitope of PRH-3 has been
mapped to the sequence VSSHYand sequences between amino
acids 224 and 251 of HTLV-1 gp46 receptor binding subunit
(Hadlock et al., 2002). It is possible that HTLV-1 interacts
through these sequences with GLUT-1 and this interaction
results in a conformational change that favors Env-mediated cell
fusion. This possibility needs to be examined at the molecular
level by using Env and GLUT-1 mutants.
In conclusion, our data demonstrate that GLUT-1 is utilized
as a receptor in CD4+ T lymphocytes and suggest a critical role
for ECL1 domain in viral entry.
Materials and methods
Cells and tissue culture
The following cell lines were purchased from the American
Type Culture Collection (ATCC, Rockville, MD): human HeLa
cells (ATCC# CCL2), murine NIH 3T3 (#CRL 1658), human
293 (CRL 1573), human HuTK-143B (CRL 8303), monkey
BSC-1 (CCL26), hamster CHO-K1 (CRL 9618), baby hamster
BHK (CRL 6281), and bovine MDBK (CRL 6071). The human
HeLa.T4 cell line (parental HeLa cells rendered positive for
human CD4 by retrovirus-mediated gene transfer; Maddon
et al., 1986) was obtained from the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
National Institutes of Health, Manassas, VA). BSC-1 and
MDBK cells were propagated in Earles modified Eagle's
medium (EMEM) containing 10% fetal bovine serum (FBS)
(HyClone, Logan, UT) and standard antibiotics. HeLa, HeLa.
T4 HuTK-143B, CHO-K1, and BHK cell lines were cultured in
Dulbecco's modified Eagle's medium (DMEM) (Quality
Biologicals, Gaithersburg, MD) containing 10% FBS, 2 mM
L-glutamine, and standard antibiotics. Human 293 cells and
NIH 3T3 cells were grown in DMEM containing 5% cosmic
calf serum (CCS) (HyClone, Logan, UT). 3T3.T4 cells were
obtained from the AIDS Reagent Program and cultured the
same way as NIH 3T3. The 3T3.T4 cells correspond to NIH
3T3 cells that constitutively express human CD4.
Construction of HTLV-1 Env cleavage mutant (Unc63)
The pHTE plasmid, which contains the HTLV-1 envelope
glycoprotein (Env), was obtained from Dr. M. Dokhelar,
France. The Env cDNA was subcloned into the EagI and
NcoI sites of the pENTR4 gateway entry plasmid (Invitrogen,
Carlsbad, CA), to generate the pE4-HTE plasmid. pE4-HTE
was then transformed into the dam/dcm deficient strain INV110
(Invitrogen), which allowed the MluNI internal site near the
GLGL mutation to be cut. Appropriate 54- and 50-mer inker
strands (Invitrogen) were chemically phosphorylated. The
linker stands had a BamHI overhang at the 5′ end and a blunt
MluNI compatible 3′ end (Fig. 1A). Samples containing 20 μg
of each complementary strand were mixed, then sequentially
incubated at 95 °C for 15 min, 76 °C for 30 s, 56 °C for 30 s,
37 °C for 15 min, and then allowed to slowly cool to room
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ligated into the pE4-HTE plasmid that had been digested with
BamHI/MluNI and dephosphorylated with Arctic Shrimp
Alkaline Phosphatase (Roche, Indianapolis, IN). The linker
had a silent change in the GLGL region that created a new
NheI site. Positive clones were identified as those that could
be digested with NheI and had retained the ligation sites.
One positive clone was subjected to direct DNA sequencing
analysis to confirm the presence of the GLGL mutation at
the cleavage site, and this clone was designated as Unc63.
Expression of Unc63 and Env 63 at the cell surface was verified
by immunofluorescent staining of transfected cells (data not
shown).
Recombinant vaccinia virus stocks were prepared by
standard procedures (Broder and Earl, 1997). The cleavage
site of HTLV-1 Env at residues 309–312 (RSRR) was changed
to GLGL in Unc63 by oligonucleotide-directed mutagenesis.
The cDNA fragment encoding Env63 or Unc63 proteins was
inserted into pSC59/T7 under T7 promoter and transfected into
TK-cells that were infected with the Western Reserve (WR)
wild-type strain of vaccinia virus. Positive plaques were
identified by dot blot hybridization as previously described
(Broder and Earl, 1997).
Generation of antibodies to synthetic peptide corresponding to
GLUT-1 ECL1
The synthetic peptide (WVHRYGESILPTTLT) corre-
sponding to amino acids 48–63 of GLUT-1 ECL1 region has
been conjugated to KLH and used to immunize chickens.
ELISA was performed to measure the titer of the antibodies
produced. Coating of ELISA plate was accomplished by adding
100 μl of peptide at a concentration of 10 μg/ml in 50 mM
carbonate buffer, pH 9.5. After removing the coating solution,
the plate was rinsed twice with distilled water and dried on
paper towel. Blocking buffer (0.1% BSA/PBS/0.02% thimer-
osal) was added and plate incubated for 2 h at room temperature
in a humid chamber. The blocking solution was removed, plate
rinsed twice with water, and dried on towel paper.
We will refer to these antibodies as GLUT-IgY to indicate the
source of this antiserum. To analyze the effect of the antibodies
on HTLV-1 Env-mediated fusion and infection, the target cells
were preincubated with increasing concentrations of the
antibodies for 30 min at 37 °C before mixing with Env-
expressing cells (fusion assay) or pseudotyped virus infection.
Isolation of GLUT-1, GLUT-3, and construction of 133333 and
311111 hybrid receptors
We employed a functional screening cDNA strategy to
isolate potential cellular receptors specific for HTLV-1. The
method has been previously described by Feng et al. (1996).
During the functional cDNA screening, we identified fraction
#32 of HeLa.T4 cDNA library as the most positive in conferring
significantly higher HTLV-1 fusion to NIH 3T3 cells (data not
shown). Quantitative RT-PCR analysis using GLUT-1 primers
indicated that this fraction is the most positive for GLUT-1cDNA (data not shown). Fraction #32 was subfractionated into
20 subfractions, which were subjected to functional cDNA
screening until a single positive clone was identified. The
isolated cDNA shared complete DNA sequence homology with
human GLUT-1 (Mueckler et al., 1985). To construct a His
tagged GLUT-1, we used our isolated GLUT-1 cDNA as a
template and the following primers for amplification: the
forward primer is: 5′-TTG CAAGCTTCCACCAGCGCAG-
CGCTGCCA-3′; the reverse His-tag GLUT-1 primer is: 5′-
GGC TCG AGT CAA TGG TGA TGG TGA TGA TGC ACT
TGG GAA TCA GCC CC-3′. To construct a His-Tagged
GLUT-3 cDNA, we used the forward primer: 5′-ACAGGAC-
GATGGGGACACAG-3′ and the reverse primer with the His
tag: 5′-GGCTCGAGTCAATGGTGATGGTGATGATGGA-
CATTGGTG GTGGTCTC-3′. The PCR reaction was per-
formed using the Platinum Pfx DNA Polymerase (Invitrogen)
and the HeLa.T4 cDNA library as a template (for GLUT-3). The
nucleotide sequence of the PCR-amplified His-tagged GLUT-1
and GLUT-3 was confirmed by DNA sequencing and found to
exactly match the published sequences (Kayano et al., 1988;
Mueckler et al., 1985).
The method we used to generate the hybrid receptor was the
same as recently described by Manel et al. (2005a). The ECL1
loops of GLUT-1 and GLUT-3 were exchanged by using the
BalI restriction site at position 206 in GLUT-1 and position 200
in GLUT-3. GLUT-1 and GLUT-3 were excised from pCDNA3
and cloned into pSC59 plasmid under vaccinia early/late
promoter (Alkhatib et al., 1996). The DNA fragments contain-
ing ECL1 domains were excised by XhoI–BalI digestion, gel
purified, and cloned into the corresponding receptor containing
plasmid.
Cell fusion assays
Env-mediated cell fusion was determined by a vaccinia-
based reporter gene assay (Nussbaum et al., 1994). The assay
analyzes fusion between two distinct cell populations, one
that expresses the potential receptor(s) along with the lacZ
gene linked to the T7 promoter (PT7-lacZ reporter), and
another that expresses HTLV-1 Env and T7 RNA polymerase
encoded by a recombinant vaccinia virus. Cell fusion is
monitored by activation of a β-galactosidase reporter gene in
response to interaction of T7 RNA polymerase with the T7
promoter in the cytoplasm of fused cells. Effector (Env-
expressing) cells were prepared by infection with recombinant
vaccinia viruses encoding either Env63 or Unc63. Expression
of PT7-lacZ reporter was accomplished by infecting the cells
with a recombinant vaccinia virus vTF7-3 encoding lacZ
under T7 promoter (Alkhatib et al., 1996). All cell
populations (effectors and targets) were incubated overnight
at 31 °C to allow expression of the vaccinia-encoded proteins.
Duplicate samples containing 105 target cells and 105 effector
cells (expressing the indicated Env protein) were mixed in 96-
well microtiter plates and incubated at 37 °C for 2–3 h. The
cell fusion activity was assayed by measuring β-galactosidase
activity in detergent-treated cell lysates (Nussbaum et al.,
1994).
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HIV-1 pseudotyped viral stocks were prepared as previ-
ously described (Agrawal et al., 2002). Briefly, the HIV-1
genome used in this protocol includes the luciferase gene
under control of the SV40 promoter in place of the HIV-1 Env
gene (HIV−Luc+Env−). Producer 293T cells were transfected
with HIV−Luc+Env− and either HTLV-1 Env63, Unc63, or
VSV G. After 60–72 h, pseudotyped viral particles were
harvested from the culture supernatants and tittered bymeasuring
the amount of p24 viral antigen using a p24 ELISA kit purchased
from Biological Products Laboratory, Frederick Cancer Re-
search and Development, Frederick, Maryland. Freshly isolated
virus was used to infect the different cell lines at a multiplicity of
infection (moi) of 1 ng/ml. The moi is based on the protein
equivalent of p24 measured in the prepared virus stock.
Human monoclonal antibodies and other commercial
antibodies
Human monoclonal antibodies (HMabs) to conformation-
dependent epitopes (PRH-3, PRH-4, PRH-7A, PRH-7B and
PRH-11A) were obtained from Dr. Steven Foung from the
University of Stanford, San Francisco, CA. Epitope mapping of
some of these monoclonal antibodies has previously been
reported (Hadlock et al., 2002). Polyclonal antibodies to human
GLUT-1 protein were purchased from Dako Corporation,
Carpentaria, CA while antibodies to GLUT-3 were purchased
from LAB VISION Corp., Fremont, CA. These antibodies were
directed against a synthetic peptide corresponding to the last 12
amino acids at the carboxyl terminus of the protein. Monoclonal
antibodies (mAbs) to Glyceraldehyde-3-PDH (GAPDH) were
purchased from BIODESIGN, Saco, ME. Antibodies to the His
tag were purchased from Santa Cruz Biotechnology, Inc., Santa
Cruz, CA.
Preparations of plasma membranes
Cells (107 cells/cell type) that were treated with 5mM sodium
azide were harvested in 5 ml of ice-cold Tris/EDTA/sucrose
buffer containing 0.25 M sucrose, 20 mM Tris (pH 7.4), 1 mM
EDTA, and 0.1 mM phenylmethylsulfonyl fluoride (PMSF) and
homogenized. The resulting homogenates were centrifuged for
20 min at 16,000 × g. The pellets were resuspended in the same
buffer, layered over a solution of containing 1.2 M sucrose,
20 mM Tris (pH7.4), and 1 mM EDTA and the suspension
centrifuged at 100,000 × g for 1 h. The plasma membranes were
aspirated from the interface, diluted with buffer lacking sucrose,
and pelleted at 27,000 × g for 36 min. The different cell samples
were homogenized and separated into supernatants and pellets
by centrifugation at 200,000 × g for 90 min.
Western blot analysis and FACS analysis
For blotting, protein samples (105 cells/lane) were sus-
pended in sample buffer, resolved by SDS-PAGE, and trans-
ferred into PVDF membranes (Immobilin, Millipore). Afterblocking with 5% nonfat dry milk, the blots were reacted with
primary antibodies against the intracellular carboxy terminus of
GLUT-1 (Dakocytomation, Carpinteria, CA) or anti-His
Tag antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA). The blots were washed three times and then incubated
with a 1:1000 dilution of biotinylated donkey anti-goat
secondary antibody (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA). After washing, the membrane was incubated
with a horseradish peroxidase (HRP)–streptavidin complex,
washed, and the specific HTLV-1 Env bands were detected by
enhanced chemiluminescence (RPN 2108, Amersham Bios-
ciences, Piscataway, NJ).
FACS analysis of GLUT-1 expression was accomplished by
indirect staining using GLUT-IgY as primary antibodies and
FITC-conjugated anti-chicken as secondary antibodies. Ap-
proximately 1 million cells were mixed with 1/100 dilution of
the chicken anti-human GLUT-IgY and incubated on ice for
30 min. After washing three times with PBS containing 1%
BSA, the cells were incubated on ice with FITC-conjugated
rabbit anti-chicken IgY (Biomeda, Foster City, CA) for 30 min.
Following incubation, the cells were washed twice with PBS
containing 1% BSA and last washed with PBS only then
resuspended in 0.5 ml PBS and analyzed using FACScan (BD
Pharmingen). Cell surface expression of GLUT-3 or GLUT-3
related chimera was accomplished by using commercial
antibodies generated against GLUT-3 ECL regions (Alpha
Diagnostic, San Antonio, TX).
Isolation of CD14+, CD19+, CD4+, and CD8+ T lymphocytes
Peripheral blood mononuclear cells (PBMCs) were isolated
from buffy coats (purchased from the Indiana Red Cross
Blood Center, Indianapolis) by Ficoll-Paque Plus (Amersham
Biosciences) centrifugation. PBMCs were used immediately
after isolation to purify CD14+, CD19+, CD4+, or CD8+
populations by positive selection using microbeads coated
with monoclonal antibodies to CD14, CD19, CD4, or CD8
according to the instructions provided by the manufacturer
(Miltenyi Biotec, Auburn, CA). The purified cells were all
cultured in RPMI containing 10% FBS and antibiotics either in
the presence or absence of phytohemagglutinin (PHA) (10 μg/
ml) (Sigma Chemicals, St. Louis) and IL-2 (50 units/ml)
(AIDS Reagents Program, NIH) for 3 days. FACS staining
with PE-conjugated antibodies to CD14, CD19, CD4, or CD8
examined the purity of cells. In case of >5% impurity, the cells
were depleted from contaminating cells (either CD4 or CD8)
by complement lysis using the kit purchased from Onelambda,
INC., Canoga Park, CA.
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